Το κακόηθες μελάνωμα του δέρματος είναι το αποτέλεσμα της κακοήθους εξαλλαγής των μελανοκυττάρων της επιδερμίδας και χαρακτηρίζεται απο συνεχώς αυξανόμενη επίπτωση και θνησιμότητα παγκοσμίως. Η αξιοσημείωτη δε ανθεκτικότητα που επιδεικνύει το προχωρημένο μεταστατικό μελάνωμα στα χημειοθεραπευτικά σχήματα και στην ακτινοθεραπεία κάνει επιτακτική την ανάγκη για νέους, πιο αποτελεσματικούς θεραπευτικούς παράγοντες. Ένας αυξανόμενος όγκος δεδομένων υποστηρίζει τη παρουσία και ενεργό συμμετοχή καρκινικών κυττάρων με ιδιότητες stem κυττάρων (cancer stem cells, CSCs) στην ανάπτυξη και μετάσταση του μελανώματος. Οι μεταγραφικοί παράγοντες EZH2, SOX2 και Oct4 αποτελούν μόρια – κλειδιά στον έλεγχο του ρυθμιστικού δικτύου του stemness των εμβρυϊκών stem κυττάρων (ESCs). Είναι πλέον γνωστό ότι η χρωματίνη στα ESCs περιλαμβάνει περιοχές με «αντιμαχόμενες» τροποποιήσεις ιστονών (bivalent domain), οι οποίες φυσιολογικά σχετίζονται είτε με ενεργή (Η3Κ4me3) ή με ανενεργή κατάσταση της χρωματίνης (H3K27me3), ενώ η απορρύθμιση των επιγενετικών μηχανισμών ελέγχου σε συγκεκριμένους γονιδιακούς τόπους έχει συσχετισθεί με τη καρκινογένεση στον άνθρωπο. Σημαντικό ρόλο στη ρύθμιση αυτών των bivalent domain φαίνεται να έχουν οι πρωτεΐνες της οικογένειας Polycomb, και ιδιαίτερα ο EZH2 που δρα σαν μεθυλοτρανσφεράση στην επιγενετική τροποποίηση H3K27. Πρόσφατα, μια σειρά από μελέτες έδειξαν ότι CScs στη διηθητική παρυφή του όγκου ενδέχεται να συμμετέχουν ενεργά στη καρκινογένεση. Επιπλέον, η ανακάλυψη ότι η βιολογική διαδικασία της επιθηλιο-μεσεγχυματικής μετάβασης (EMT) οδηγεί υποπληθυσμούς καρκινικών κυττάρων εντός του όγκου να αποκτήσουν ιδιότητες stem κυττάρων, φαίνεται να αποτελεί τον σύνδεσμο μεταξύ μετάστασης και κατάστασης πολυδυναμίας (stemness). Σύμφωνα λοιπόν με τη θεώρηση αυτή, είναι πιθανό τα CSCs να εντοπίζονται κυρίως στη διηθητική παρυφή ενός όγκου, ενώ επιπλέον οι ιδιότητες stem κυττάρων που έχουν αποκτήσει είναι το αποτέλεσμα κυρίως της ΕΜΤ. Σε αυτό το πλαίσιο, παρουσιάζει επομένως εξαιρετικό ενδιαφέρον η προσεκτική και στοχευμένη εκτίμηση της ανοσοϊστοχημικής έκφρασης παραγόντων που σχετίζονται με τα stem κύτταρα στην διηθητική παρυφή του μελανώματος, και αυτός ήταν ένας από τους στόχους της παρούσας διαδακτορικής διατριβής. Σκοπός. Ο σκοπός της παρούσας διδακτορικής διατριβής είναι η μελέτη της έκφρασης των μεταγραφικών παραγόντων EZH2, Oct4, SOX2 όπως επίσης και την παρουσία των επιγενετικών τροποποιήσεων H3K4me2 and H3K27me3 (bivalent domain) στο κακόηθες μελάνωμα του δέρματος. Παράλληλα, μελετήθηκε η πιθανότητα αναγνώρισης και στοχοποίησης καρκινικών κυττάρων με ιδιότητες stem κυττάρων, με ιδιαίτερη έμφαση στη διηθητική παρυφή του όγκου. Υλικό και μέθοδος. Το ποσοστό κυττάρων με ανοσοθετικότητα για τα αντισώματα έναντι των μεταγραφικών παραγόντων EZH2, SOX2 και Oct4 όπως επίσης και των επιγενετικών τροποποιήσεων H3K4me2 and H3K27me3 εκτιμήθηκε σε 89 δείγματα ιστών από 79 ασθενείς με κακόηθες μελάνωμα 250 του δέρματος, εφαρμόζοντας τη μέθοδο της ανοσοϊστοχημείας. Για την επιλογή των κατάλληλων δειγμάτων έγινε ανασκόπηση των αρχείων του εργαστηρίου Παθολογικής Ανατομικής του Πανεπιστημιακού Γενικού Νοσοκομείου Πατρών των ετών 2001 έως 2010. Από αυτό το σύνολο των 89 δειγμάτων τα 70 αφορούν πρωτοπαθές μελάνωμα δέρματος, ενώ τα υπόλοιπα 19 προέρχονται από υλικό που εξαιρέθηκε κατά τη χειρουργική εκτομή του μεταστατικού μελανώματος. Επιπλέον 14 δείγματα περιείχαν εκτός από καρκινικά κύτταρα μελανώματος και κύτταρα σπίλων. Στην παρούσα μελέτη χρησιμοποιήθηκε το σύστημα ανίχνευσης EnVision (Envision, Dako, USA) ή MACH4 Universal HRP-Polymer Detection (Biocare Medical, USA) και πρωτογενή αντισώματα έναντι των EZH2 (Novocastra Laboratories Ltd, UK), SOX2 (R&D Systems, Inc.), Oct4 (Santa Cruz Biotechnology, Inc), H3K4me2 (Cell Signaling Technology, USA) και H3K27me3 (Cell Signaling Technology, USA). Σε κάθε περιστατικό και για κάθε δείκτη εκτιμήθηκε το ποσοστό των καρκινικών κυττάρων που εμφάνιζαν θετική ανοσοχρώση (Labeling Index, LI). Η καταμέτρηση των θετικών κυττάρων πραγματοποιήθηκε σε μεγάλης μεγέθυνσης πεδίο (400X). Η στατιστική ανάλυση έγινε με τη χρήση του SPSS στατιστικού πακέτου (SPSS©, Release 19.0). Τιμές p<0.05 θεωρήθηκαν ως στατιστικά σημαντικές. Αποτελέσματα. Πυρηνική χρώση ανιχνεύθηκε για τα αντισώματα έναντι των EZH2, H3K4me2 και H3K27me3, ενώ αντίθετα βρέθηκε πυρηνική και κυτταροπλασματική έκφραση για τους παράγοντες SOX2 και Oct4. Παρατηρήθηκε ανομοιογενές προφίλ ανοσοθετικότητας στα κύτταρα μελανώματος με σημαντικά αυξημένο ποσοστό καρκινικών κυττάρων με θετική ανοσοχρώση H3K4me2 και H3K27me3 στη διηθητική παρυφή του όγκου. Αντίστοιχη τάση για αυξημένη έκφραση έδειξε και ο μεταγραφικός παράγοντας EZH2, χωρίς όμως η διαφορά να είναι στατιστικά σημαντικά, ενώ παρατηρήθηκε και σε ορισμένες μεμονωμένες περιπτώσεις με τον SOX2. Όσον αφορά τον ΕΖΗ2, βρέθηκε σημαντική αύξηση των επιπέδων του παράγοντα στα κύτταρα μελανώματος σε σχεση με τα σπιλοκύτταρα (p=0.02). H πυρηνική έκφραση SOX2 ήταν σημαντικά υψηλότερη στα κύτταρα μελανώματος σε σχέση με τα κερατινοκύτταρα της βασική στιβάδας (p=0.02), όπως επίσης και στα σπιλοκύτταρα συγκριτικά με τα κερατινοκύτταρα της βασικής (p=0.0016) και της υπερβασικής στιβάδας (p=0.027). Η συσχέτιση της πυρηνικής έκφρασης με διάφορες παραμέτρους των ασθενών έδεξε υψηλότερα επίπεδα SOX2 στα πρωτοπαθή σε σχέση με τα μεταστατικά μελανώματα (p=0.045), στα κύτταρα μελανώματος με πάχος όγκου κατά Breslow <1mm (p=0.023), χωρίς εξέλκωση (p=0.009) και με αριθμό μιτώσεων ≤6 μιτ/mm2 (p=0.016). Τα επίπεδα πυρηνικής έκφρασης Oct4 βρέθηκαν υψηλότερα στα σπιλοκύτταρα σε σχέση με τα κερατινοκύτταρα (p<0.001) αλλά και με τα κύτταρα μελανώματος (p=0.004). Η μελέτη ωστόσο της κυτταροπλασματικής ανοσοθετικότητας έδειξε σημαντική μείωση των επιπέδων Oct στα κύτταρα μελανώματος σε σχέση με τα κερατινοκύτταρα της υπερβασικής στιβάδας (p<0.001), όπως επίσης στα μεταστατικά σε σχέση με τα πρωτοπαθή μελανώματα (p=0.025). Αξιοσημείωτο είναι επίσης ότι το προφίλ έκφρασης του Oct4 βρέθηκε σε ορισμένες περιπτώσεις να αυξάνεται τοπικά στα ενδοθηλιακά κύτταρα αγγείων εντός των μελανωμάτων. Τα μελανώματα με υψηλό επίπεδο διήθησης κατά Clark (IV-V) (p=0.038) ή μεγάλο 251 πάχος όγκου κατά Breslow (>1mm) (p<0.001) εμφάνισαν χαμηλότερο ποσοστό καρκινικών κυττάρων με ανοσοθετικότητα για το αντίσωμα H3K4me2 σε σχέση με τους όγκους με μικρότερο βαθμό διήθησης. Επιπλέον, παρατηρήσαμε ότι οι μεταστατικοί όγκοι είχαν χαμηλότερα ποσοστά θετικής ανοσοχρώσης και για τις δύο επιγενετικές τροποποιήσεις, H3K4me2 και H3K27me3, συγκριτικά με τους πρωτοπαθείς όγκους (p=0.0065 και p=0.027 αντίστοιχα). Τέλος, η ανάλυση της παράλληλης ανοσοϊστοχημικής έκφρασης στα κύτταρα μελανώματος έδειξε θετική συσχέτιση των δύο επιγενετικών τροποποιήσεων (p<0.01), όπως επίσης και μεταξύ του EZH2 και της επιγενετικής τροποποίησης H3K27me3 (p=0.03). Ισχυρή συσχέτιση βρέθηκε παρομοίως μεταξύ των επιπέδων έκφρασης Oct4 και SOX2, τόσο για την πυρηνική όσο και την κυτταροπλασματική εντόπιση (p<0.001 και p<0.001 αντίστοιχα). Συμπεράσματα. Λαμβάνοντας υπόψη τη λειτουργική σημασία των τριών υπό μελέτη μεταγραφικών παραγόντων και του ρόλου των επιγενετικών μηχανισμών στην καρκινογένεση, τα ευρήματα μας εισηγούνται ότι οι ΕΖΗ2, SOX2, Oct4 όπως επίσης και οι επιγενετικές τροποποιήσεις Η3Κ4me3 και H3K27me3 αποτελούν εν δυνάμει δείκτες καρκινικών stem κυττάρων στο κακόηθες μελάνωμα, και ιδιαίτερα στη διηθητική παρυφή του όγκου. Η υπόθεση αυτή πρέπει να διεριευνηθεί περαιτέρω, καθώς θα μπορούσε να αποτελέσει, σε συνδυασμό και με άλλες μελέτες, ένα μικρό βήμα προς τη κατεύθυνση της στοχευμένης αντικαρκινικής θεραπείας του μελανώματος στα πλαίσια της Ιατρικής του μέλλοντος. / Cutaneous malignant melanoma originates from melanocytes and is characterized by constantly growing incidence and mortality rates world-wide. The substantial unresponsiveness of advanced metastatic melanomas to most forms of chemotherapy and radiation indicates an urgent need for more effective agents to overcome chemoresistance. Accumulating evidence strongly suggests the presence and involvement of cancer cells with properties of stem cells (CSCs) in the initiation, progression and metastasis of malignant melanoma. EZH2, SOX2 and Oct4 represent crucial components of the reciprocal regulatory circuit that controls stemness. Genome-wide analyses of chromatin states of embryonic stem and progenitor cells suggest a ‘bivalent’ colocalization of the activating H3K4 methylation and the repressive H3K27me3 in development-associated genes, while the misregulation of histone modifications on specific residues actively contributes to human cancer. PcG proteins and mainly EZH2 are responsible for maintaining the balance of the bivalent chromatin domain through the methylation of H3K27. Recently a number of studies have shown that cancer cells with properties of stem cells at the tumor invasion front might be involved in the development of metastasis. The discovery that the epithelial to mesenchymal transition (EMT) generates cells with properties of stem cells and a more invasive and metastatic phenotype, brings a connection between metastasis and stem-cell state. According to this model, cells with stem cell properties are located predominantly at the invasion front of the tumor and can derive through the acquisition of transient EMT phenotype. In this context, a comparative analysis of the expression profile of putative CSC markers between the invasion front and the inner tumor mass could test this hypothesis in the case of cutaneous melanoma as well. Purpose. Taking these data into account, we performed the current study in order to evaluate the immunohistochemical expression of EZH2, SOX2 and Oct4 as well as H3K4me2 and H3K27me3, which constitute stem cell-like "bivalent"domains, in cutaneous malignant melanoma, investigating besides the potential identification of cancer cells with stem cells properties at the invasion front of the tumor. Materials and methods. Expression of EZH2, SOX2, Oct4, H3K4me2 and H3K27me3 was evaluated in 89 malignant melanoma (MM) lesions, deriving from 79 patients, using immunohistochemistry, on formalin-fixed paraffin-embedded tissue sections. The analyzed cases were accessioned over the time interval 2001-2010 and retrieved from an electronic database maintained by the Department of Pathology of the University General Hospital of Patras (Rion, Greece). The sample consists of 70 primary and 19 metastatic specimens. 14 specimens contained both melanoma cells and nevus cells. Analysis and comparative studies were carried out on the expression of the proteins tested in nevus cells (where existed), melanoma cells, melanoma cells at the invasion front, basal and suprabasal 253 keratinocytes as well. Polymer based technique (Envision, Dako, USA) or MACH4 Universal HRPPolymer Detection (Biocare Medical, USA) and primary antibodies against EZH2 (Novocastra Laboratories Ltd, UK), SOX2 (R&D Systems, Inc.), Oct4 (Santa Cruz Biotechnology, Inc), H3K4me2 (Cell Signaling Technology, USA) and H3K27me3 (Cell Signaling Technology, USA) were used. In each case, the percentage of cells exhibiting positive staining was determined. Cell counts were performed at a 400X magnification. Data were analyzed using the SPSS statistical package (SPSS©, Release 19.0). The level of significance was set at p-value <0.05. Results. The three markers studied, EZH2, H3K4me2 and H3K27me3, were identified in the cell nuclei of melanoma cells, nevus cells and normal epidermal keratinocytes, while SOX2 και Oct4 showed nuclear as well as cytoplastik expression. A specific distribution pattern of H3K4me2 and H3K27me3 was found, as stronger levels were localized at the invasion front of the tumor (p=0.034 and p<0.01 respectively). A similar trend was also observed for EZH2, whithout achieving however statistical significance (p=0.08), and similarly for SOX2 in a few sporadic cases. Significantly increased EZH2 immunohistochemical expression was observed in melanoma cells with respect to nevus cells (p=0.02). Nuclear SOX2 levels were also higher in melanoma cells than basal keratinocytes (p=0.02) and in nevus cells than basal keratinocytes (p=0.0016) and suprabasal keratinocytes (p=0.027). Furthermore LIs in melanoma cells presented significantly higher values in primary with respect to metastatic malignant melanoma lesions (p=0.045) as well as in melanoma cells with low Breslow’s depth (≤1mm) (p=0.023), under the absence of ulceration (p=0.009) and with low (≤6/mm2) mitotic rate (p=0.016). As well as nuclear expression of Oct4 is concerned, it was found increased in nevus cells with compared to keratinocytes (p<0.001) and melanoma cells (p=0.004). Cytoplastic expression of Oct4 followed an opposite trend, with decreasing levels in melanoma cells with respekt to suprabasal keratinocytes (p<0.001) and in metastic compared to to primary melanoma cases (p=0.025). Remarkably occasionally increased Oct4 expression in endothelial cells of the tumor microvasculature in melanoma tissues was observed. Furthermore, H3K4me2 and H3K27me3 levels were lower in metastatic with respect to primary melanoma cases (p=0.0065 and p=0.027 respectively). Advanced melanoma demonstrated significantly lower H3K4 immunohistochemical expression than cases of lowest Clark’s level (I) (p=0.038) or low Breslow’s depth (≤1 mm) (p<0.001). Moreover, EZH2 expression in melanoma cells was higher compared to nevus cells (p=0.02). Finally statistical analysis further revealed a positive correlation in melanoma cells betwenn EZH2 and H3K27me3 (p=0.03), H3K4me2 and H3K27me3 (p<0.01), as well as between Oct4 and SOX2 for both nuclear and cytoplastik expression (p<0.001 and p<0.001 respektively). Conclusions. Our results suggest the possibility that combined immunohistochemical expression of EZH2, SOX2, Oct4, H3K4me2 and H3K27me3 might identify cancer cells with potential stem cell properties, particularly at the invasion front of this malignancy. This hypothesis should be further investigated, as many of the epigenetic changes are reversible via pharmacologic manipulations and new CSC-directed therapies, overpassing the resistance of advanced melanoma, may be developed.

Colony-stimulating factor 1 receptor (CSF1R, Fms) is an integral transmembrane glycoprotein with tyrosine specific protein kinase activity that it is found on the mononuclear phagocytes to promote their survival, proliferation and differentiation. Colony-stimulating factor 1 (CSF-1), also known as M-CSF, is a protein ligand that acts on the CSF1R. There is a variable association of Fms with the stem cell marker CD34 on acute myeloid leukemia (AML) cells and this suggests different structures of the AML hierarchy in different patients. Mouse stromal cells (MS-5) were transduced with a plasmid containing human CSF-1 because mouse CSF-1 is inactive on human CSF1R. Results show that AML cells cultured with CSF-1-expressing stroma had a much better growth and survival than the control stroma, suggesting that CSF-1 might be a stimulating factor for the growth of leukemic stem cells.

Pluripotent stem cells provide the opportunity to study human cardiogenesis in vitro, and are a renewable source of tissue for drug testing and disease models, including replacement cardiomyocytes that may be a useful treatment for heart failure. Typically, differentiation is initiated by forming spherical cell aggregates wherein an extraembryonic endoderm (ExE) layer develops on the surface. Given that interactions between endoderm and mesoderm influence embryonic cardiogenesis, we examined the impact of human embryonic stem cell (hESC) aggregate size on endoderm and cardiac development. We first demonstrated aggregate size control by micropatterning hESC colonies at defined diameters and transferring the colonies to suspension. The ratio of endoderm (GATA-6) to neural (PAX6) gene and protein expression increased with decreasing colony size. Subsequently, maximum mesoderm and cardiac induction occurred in larger aggregates when initiated with endoderm-biased hESCs (high GATA-6:PAX6), and in smaller aggregates when initiated with neural-biased hESCs (low GATA-6:PAX6). Additionally, incorporating micropatterned aggregates in a stirred suspension bioreactor increased cell yields and contracting aggregate frequency. We next interrogated the relationship between aggregate size and endoderm and cardiac differentiation efficiency in size-controlled aggregates, generated using forced aggregation, in defined cardiogenic medium. An inverse relationship between endoderm cell frequency (FoxA2+ and GATA6+) and aggregate size was observed, and cardiogenesis was maximized in mid-size aggregates (1000 cells) based on frequency of cardiac progenitors (~50% KDRlow/C-KITneg) on day 5 and cardiomyocytes (~24% cTnT+) on day 16. To elucidate a relationship between endoderm frequency and cardiac differentiation efficiency, aggregates were initiated with varying frequencies of ExE progenitors (SOX7-overexpressing hESCs). Maximum cardiomyocyte frequencies (~27%) occurred in aggregates formed with 10 to 25% ExE progenitors. These findings suggest a geometric relationship between aggregate size and ExE differentiation efficiency subsequently impacts cardiomyocyte yield, elucidating a mechanism for endogenous control of cell fate through cell-cell interactions in the aggregate.

No description available.

The fungal disease smut (causal agent: Ustilago scitaminea H. & P. Sydow) and stalk borer Eldana saccharina Walker place major constraints on sugarcane agriculture in South Africa. The best approach for management is the introduction of resistant cultivars; however, conventional field-based screening for pest and disease resistance is a lengthy process. This study evaluated in vitro techniques combined with artificial inoculation of 12 week old in vitro plantlets and 8-10 week old embryogenic calli as rapid screening methods. Preliminary investigations were conducted on cultivars with known field ratings to smut and E. saccharina: NCo376, N26 and N39; and 5 „test‟ cultivars, whose identities were undisclosed until completion of experiments, were used to assess the accuracy of protocols. Infective U. scitaminea sporidia generated from teliospores, were used as inocula. Development of a callus protocol was unsuccessful due to sporidial and mycelial overgrowth, despite addition of a contact fungicide, Dithane M-45® (0.025 g/l) and a biocide/fungicide, PPMTM (5 ml/l), to media. Plantlet inoculation by injection, 1 cm above the apical meristem, resulted in 12% and 20% of smut susceptible NCo376 plantlets producing smut whips after 5 weeks when inoculated with 1 x 106 and 1 x 109 sporidia/ml, respectively. Smut whip production in 5 of the 8 (63%) cultivars inoculated with the lower sporidial concentration correlated with their field resistance ratings. In addition, whips harvested from in vitro plantlets were a valuable source of aseptic teliospores for future research. Ongoing work involves inoculation of NCo376 calli with such teliospores and maintenance on medium with PPMTM - emergence of whips from plantlets remains to be assessed. The E. saccharina screening protocol involved surface decontamination of eggs with 1% sodium hypochlorite (NaOCl) for 15 min. Feeding bioassays were conducted by placement of first instar larvae on in vitro plantlets and calli for 3 and 2 weeks, respectively. Larval mass, length and percentage infestation were recorded. Although greater larval size was expected in susceptible compared with resistant cultivars, the results did not support this. Significant differences in plantlet infestation were observed between susceptible (94-98%) and resistant (72-86%) lines. No significant differences were found in the callus feeding bioassay. However, a 24 h callus choice bioassay which investigated larval preference between callus genotypes compared with NCo376, showed significant differences and correctly discerned cultivar susceptibility according to field ratings. / Thesis (M.Sc.)-University of KwaZulu-Natal, Westville, 2010.

Pluripotent stem cells provide the opportunity to study human cardiogenesis in vitro, and are a renewable source of tissue for drug testing and disease models, including replacement cardiomyocytes that may be a useful treatment for heart failure. Typically, differentiation is initiated by forming spherical cell aggregates wherein an extraembryonic endoderm (ExE) layer develops on the surface. Given that interactions between endoderm and mesoderm influence embryonic cardiogenesis, we examined the impact of human embryonic stem cell (hESC) aggregate size on endoderm and cardiac development. We first demonstrated aggregate size control by micropatterning hESC colonies at defined diameters and transferring the colonies to suspension. The ratio of endoderm (GATA-6) to neural (PAX6) gene and protein expression increased with decreasing colony size. Subsequently, maximum mesoderm and cardiac induction occurred in larger aggregates when initiated with endoderm-biased hESCs (high GATA-6:PAX6), and in smaller aggregates when initiated with neural-biased hESCs (low GATA-6:PAX6). Additionally, incorporating micropatterned aggregates in a stirred suspension bioreactor increased cell yields and contracting aggregate frequency. We next interrogated the relationship between aggregate size and endoderm and cardiac differentiation efficiency in size-controlled aggregates, generated using forced aggregation, in defined cardiogenic medium. An inverse relationship between endoderm cell frequency (FoxA2+ and GATA6+) and aggregate size was observed, and cardiogenesis was maximized in mid-size aggregates (1000 cells) based on frequency of cardiac progenitors (~50% KDRlow/C-KITneg) on day 5 and cardiomyocytes (~24% cTnT+) on day 16. To elucidate a relationship between endoderm frequency and cardiac differentiation efficiency, aggregates were initiated with varying frequencies of ExE progenitors (SOX7-overexpressing hESCs). Maximum cardiomyocyte frequencies (~27%) occurred in aggregates formed with 10 to 25% ExE progenitors. These findings suggest a geometric relationship between aggregate size and ExE differentiation efficiency subsequently impacts cardiomyocyte yield, elucidating a mechanism for endogenous control of cell fate through cell-cell interactions in the aggregate.

The loss of regenerative capacity of bone, from fetal to adult to aged animals, has been attributed not only to a decline in the function of cells involved in bone formation but also to alterations in the bone microenvironment that occur through development and aging, including extracellular matrix (ECM) composition and growth/trophic factor content. In the development of novel treatments for bone repair, one potential therapeutic goal is the restoration of a more regenerative microenvironment, as found during embryonic development. One approach to creating such a microenvironment is through the use of stem cells. In addition to serving as a differentiated cell source, pluripotent stem cells, such as embryonic stem cells (ESCs), may possess the unique potential to modulate tissue environments via local production of ECM and growth factors. ESC-produced factors may be harnessed and delivered to promote functional tissue regeneration. Such an approach to generate a naturally derived, acelluar therapy has been employed successfully to deliver osteoinductive factors found within adult bone, in the form of demineralized bone matrix (DBM), but the development of treatments derived instead from developing, more regenerative tissues or cells remains attractive. Furthermore, the derivation of regenerative materials from an ESC source also presents the added benefit of eliminating donor to donor variability of adult, cadaveric tissue derived materials, such as DBM. Thus, the objective of this project was to examine the osteoinductive potential harbored within the embryonic microenvironment, in vitro and in vivo. The osteogenic differentiation of mouse ESCs as embryoid bodies (EBs) was evaluated in response to phosphate treatment, in vitro, including osteoinductive growth factor production. The osteoinductivity of EB-derived material (EBM) was then compared to that of adult tissue-derived DBM, in vivo. Phosphate treatment enhanced osteogenic differentiation of EBs. EBM derived from phosphate treated EBs retained bioactive, osteoinductive factors and induced new bone formation, demonstrating that the microenvironment within osteogenic EBs can be harnessed in an acellular material to yield in vivo osteoinductivity. This work not only provides new insights into the dynamic microenvironments of differentiating stem cells but also establishes an approach for the development of an ESC-derived, tissue specific therapy.

<p><p> Articular cartilage is a smooth connective tissue that covers the ends of bones and protects joints from wear. Cartilage has a poor healing capacity, and the lack of treatment options motivates the development of tissue engineering strategies. The widespread cartilage degeneration associated with osteoarthritis (OA) is dramatically accelerated by joint injury, but the defined initiating event presents a therapeutic window for preventive treatments. In vitro model systems allow investigation of OA risk factors and screening of potential therapeutics. This dissertation develops stem-cell based strategies to 1) treat cartilage injury and OA using tissue-engineered cartilage, 2) prevent the development of OA by delivering stem cells to the joint after injury, and 3) study cartilage by establishing systems to model genetic and environmental contributors to OA.</p><p> Adipose-derived stem cells (ASCs) and bone marrow-derived mesenchymal stem cells (MSCs) are promising human adult cell sources for cartilage tissue engineering, but require distinct chondrogenic conditions. As compared to ASCs, MSCs demonstrated enhanced chondrogenesis in both alginate beads and cartilage-derived matrix scaffolds. </p><p> We hypothesized that MSC therapy would prevent post-traumatic arthritis (PTA) by altering the balance of inflammation and regeneration. Highly purified MSCs (CD45-TER119-PDGFR&#945;+Sca-1+) rapidly expanded under hypoxic conditions. Unexpectedly, MSCs from control C57BL/6 (B6) mice proliferated and differentiated more than MSCs from MRL/MpJ (MRL) "superhealer" mice. We injected B6 or MRL MSCs into mouse knees immediately after fracture, and MSCs of either strain were sufficient to prevent PTA. </p><p> Genetically reprogramming adult cells into induced pluripotent stem cells (iPSCs) generates large numbers of patient-matched cells with chondrogenic potential for therapy and cartilage modeling. We produced murine iPSC-derived cartilage constructs with a multi-phase approach involving micromass culture with bone morphogenetic protein-4, flow cytometry cell sorting of chondrocyte-like cells, monolayer expansion, and pellet culture with transforming growth factor-beta 3. Successful differentiation was confirmed by increased chondrogenic gene expression, robust synthesis of glycosaminoglycans and type II collagen, and the repair of an in vitro cartilage defect. </p><p> The diverse applications pursued in this research illustrate the power of stem cells to deepen the understanding of cartilage and guide the development of therapies to prevent and treat cartilage injury and OA.</p> / Dissertation

The regenerative potential of adult stem cell populations within the human body bears great promises for their use in regenerative medicine. The bone marrow (BM) harbours two different types of adult stem cells, haematopoietic stem and progneitor cells (HSPCs) and multipotent mesenchymal stromal cells (MSCs), which are tightly regulated in their distinct anatomically defined niches by multiple cues such as cytokines, cell-cell contacts, the extracellular matrix (ECM) and the physical microenvironment. The ex vivo expansion of these cells for applications in regenerative therapies is of great interest and several biomaterial approaches attempt to mimic the natural BM niche and its components to control stem cell maintenance and differentiation. However, as of now the complexity of such stem cell niches is hard to recapitulate. Towards this goal, this work was focussing on the ECM environment of BM stem cells and was set out to engineer improved in vitro culture systems. MSC themselves are one of the most important cell types within the BM that secrete and construct ECM-networks and thereby shape the microenvironment of the residing cells. The potential of primary human BM-MSC to secrete ECM in vitro has been exploited to generate niche-like ECM surrogates in a robust and versatile format. Application of decellularisation regimes allowed the fabrication of complex matrices which demonstrated suprastructural, compositional and physicochemical properties compareable to those of the native BM-ECM environment. Reliable stability and reproduciblity was achieved by a dedicated procedure of maleic anhydride co-polymer-mediated covalent binding of fibronectin and subsequent anchorage of cell-secreted ECM molecules. As a result of the high reproducibility, a complete proteomic register of ECM molecules was obtained in combination with determining the complex fibrillar and soft gel-like characteristics of MSC-derived matrices. Based on the established BM niche-like substrate, the impact of extracellular matrices on MSC and HSPC ex vivo behavior has been explored. Both cell types demonstrated strong adhesion to ECM substrates and depicted a changed cellular morphology upon contact with native ECM structures compared to standard culture substrates or simple ECM protein coatings, indicating an intense interplay between the cell and the microenvironment. MSC that re-grew into their own matrices have shown advantageous proliferation and cytokine secretion levels as well as enhanced differentiation intensity (upon differentiation induction) compared to MSC that were cultured on less complex substrates. Similarly, HSPC were also instructed for enhanced expansion on MSC-derived matrices without exhaustion of stem cell-marker expressing progenitor cells. The efficiency of these matrices was related to their ability to mimic the native composite suprastructure, ligand nano-topography, molecular composition and physical properties of natural BM ECM environments. The data obtained within this thesis set the ground for a more rational design of artificial stem cell niches with defined and distinct properties, offering exciting options for the in-depth analysis and understanding of stem cell regulation by exogenous cues.

We sought to determine whether activation of the Wnt signaling pathway altered the function of hNSCs in vitro. We took three approaches to activate Wnt signaling: Wnt3a, constitutively stabilized β-catenin (ΔN90), and the GSK3 inhibitor BIO. While Wnt3a and ΔN90 had no effect on proliferation in both stem cell (+EGF/FGF) and differentiating (-EGF/FGF) conditions, BIO reduced proliferation in both. All methods of Wnt signaling activation promoted neuronal lineage commitment during hNSC differentiation. Furthermore, BIO was able to induce mild neuronal differentiation in stem cell conditions, suggesting that GSK3-inhibition interferes with several pathways to regulate hNSC fate decisions. We also probed BTSC function using BIO-mediated GSK3 inhibition. We found that in stem cell conditions, BIO was able to induce neuronal differentiation, decrease proliferation, and induce cell cycle arrest. Together this data suggests that GSK3-inhibition, possibly through activation of Wnt signaling, may offer a novel mechanism for the differentiation treatment of glioblastomas.